Product Introduction
Bioactivity


英文名: BZAD01

描述: BZAD01 是一种选择性 NMDA NR1A/2B 受体拮抗剂。

体内活性: Parkinsonism was induced by microinjection of the toxin, 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) of 40 Sprague-Dawley rats. Parkinsonism and the efficacy of drugs were assessed using a battery of behavioural tests including balance beam, apomorphine-induced rotation, body axis bias or "curling", head position bias and disengage sensorimotor latency test. The main effects were that BZAD01 co-administration prevented chronic levodopa-induced potentiation of apomorphine rotation. However levodopa-treated rats were slower than either controls or BZAD-01-treated rats in the locomotor test[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/ml (151.82 mM)


关键字: Inhibitor | NR2B | NMDA | iGluR | Ionotropic glutamate receptors | BZAD01 | inhibit

相关产品: DQP 1105 | Ro 8-4304 | Spermidine trihydrochloride | 4-PPBP maleate | Traxoprodil | Rapastinel acetate | Transtorine | 5,7-Dichlorokynurenic acid | AV-101 | TCN 201

相关库: Anti-Neurodegenerative Disease Compound Library | Neurotransmitter Receptor Compound Library | Anti-Parkinson's Disease Compound Library | Bioactive Compounds Library Max | Antidepressant Compound Library | Neuronal Signaling Compound Library | Inhibitor Library | Anti-Alzheimer's Disease Compound Library | Bioactive Compound Library